| Line |
Label |
Object Class |
Period Type |
Balance |
Report ElementName |
| 1 |
0001000 - Document - Document and Entity Information Document |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument |
| 2 |
Implied Table |
Table |
* |
* |
implied:Table |
| 3 |
Document And Entity Information [Abstract] |
Abstract |
|
|
oncyf:DocumentAndEntityInformationAbstract |
| 4 |
Entity Registrant Name |
Concept (Text/String) |
For Period |
|
dei:EntityRegistrantName |
| 5 |
Entity Central Index Key |
Concept (CIK Number) |
For Period |
|
dei:EntityCentralIndexKey |
| 6 |
Current Fiscal Year End Date |
Concept (Month/Day) |
For Period |
|
dei:CurrentFiscalYearEndDate |
| 7 |
Entity Filer Category |
Concept (Filer Category) |
For Period |
|
dei:EntityFilerCategory |
| 8 |
Document Type |
Concept (Submission Type) |
For Period |
|
dei:DocumentType |
| 9 |
Document Period End Date |
Concept (Date) |
For Period |
|
dei:DocumentPeriodEndDate |
| 10 |
Document Fiscal Year Focus |
Concept (Year) |
For Period |
|
dei:DocumentFiscalYearFocus |
| 11 |
Document Fiscal Period Focus |
Concept (Fiscal Period) |
For Period |
|
dei:DocumentFiscalPeriodFocus |
| 12 |
Amendment Flag |
Concept (Yes/No) |
For Period |
|
dei:AmendmentFlag |
| 13 |
Entity Common Stock, Shares Outstanding |
Concept (Shares) |
As Of |
|
dei:EntityCommonStockSharesOutstanding |
| 14 |
Entity Shell Company |
Concept (Yes/No) |
For Period |
|
dei:EntityShellCompany |
| 15 |
Entity Emerging Growth Company |
Concept (Yes/No) |
For Period |
|
dei:EntityEmergingGrowthCompany |
| 16 |
Entity Well-known Seasoned Issuer |
Concept (Yes/No) |
For Period |
|
dei:EntityWellKnownSeasonedIssuer |
| 17 |
Entity Voluntary Filers |
Concept (Yes/No) |
For Period |
|
dei:EntityVoluntaryFilers |
| 18 |
Entity Current Reporting Status |
Concept (Yes/No) |
For Period |
|
dei:EntityCurrentReportingStatus |
| 19 |
Entity Public Float |
Concept (Monetary) |
As Of |
Credit |
dei:EntityPublicFloat |
| 20 |
1001000 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition |
| 21 |
Implied Table |
Table |
* |
* |
implied:Table |
| 22 |
Statement of financial position [abstract] |
Abstract |
|
|
ifrs-full:StatementOfFinancialPositionAbstract |
| 23 |
Assets |
Abstract |
|
|
ifrs-full:AssetsAbstract |
| 24 |
Current assets |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 25 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 26 |
Contract receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentReceivablesFromContractsWithCustomers |
| 27 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherCurrentReceivables |
| 28 |
Prepaid expenses |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentPrepaidExpenses |
| 29 |
Total current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 30 |
Non-current assets |
Abstract |
|
|
ifrs-full:NoncurrentAssetsAbstract |
| 31 |
Property and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 32 |
Total non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 33 |
Total assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 34 |
Liabilities And Shareholders’ Equity |
Abstract |
|
|
ifrs-full:EquityAndLiabilitiesAbstract |
| 35 |
Current Liabilities |
Abstract |
|
|
ifrs-full:CurrentLiabilitiesAbstract |
| 36 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 37 |
Contract liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentContractLiabilities |
| 38 |
Other liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentLiabilities |
| 39 |
Total current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 40 |
Non-current liabilities |
Abstract |
|
|
ifrs-full:NoncurrentLiabilitiesAbstract |
| 41 |
Contract liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentContractLiabilities |
| 42 |
Other liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 43 |
Total non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 44 |
Total liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 45 |
Commitments and contingencies |
Concept (Monetary) |
As Of |
Credit |
oncyf:CommitmentsAndContingencies1 |
| 46 |
Shareholders’ equity |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 47 |
Share capital Authorized: unlimited Issued: December 31, 2018 – 17,399,749 December 31, 2017 – 141,805,722 pre-consolidation December 31, 2017 – 14,926,840 post-consolidation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 48 |
Warrants |
Concept (Monetary) |
As Of |
Credit |
oncyf:WarrantsandRightsOutstanding |
| 49 |
Contributed surplus |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AdditionalPaidinCapital |
| 50 |
Accumulated other comprehensive income |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AccumulatedOtherComprehensiveIncome |
| 51 |
Accumulated deficit |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 52 |
Total shareholders’ equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 53 |
Total liabilities and equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAndLiabilities |
| 54 |
1001001 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical |
| 55 |
Disclosure of reclassification of financial assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReclassificationOfFinancialAssetsTable |
| 56 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 57 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 58 |
Pre-Consolidation |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 59 |
Disclosure of reclassification of financial assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReclassificationOfFinancialAssetsLineItems |
| 60 |
Share capital issued (shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 61 |
1002000 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss |
| 62 |
Implied Table |
Table |
* |
* |
implied:Table |
| 63 |
Profit or loss [abstract] |
Abstract |
|
|
ifrs-full:IncomeStatementAbstract |
| 64 |
Expenses |
Abstract |
|
|
ifrs-full:ExpenseByNatureAbstract |
| 65 |
Research and development |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 66 |
Operating |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OperatingExpense |
| 67 |
Loss before the following |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 68 |
Interest |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnCashAndCashEquivalents |
| 69 |
Loss before income taxes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 70 |
Income tax expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 71 |
Net loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 72 |
Other comprehensive income (loss) items that may be reclassified to net loss |
Abstract |
|
|
ifrs-full:OtherComprehensiveIncomeAbstract |
| 73 |
Translation adjustment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation |
| 74 |
Net comprehensive loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 75 |
Basic and diluted loss per common share (cad per share) |
Concept (Share) |
For Period |
|
ifrs-full:BasicAndDilutedEarningsLossPerShare |
| 76 |
Weighted average number of shares (basic) |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 77 |
Weighted average number of shares (diluted) |
Concept (Shares) |
For Period |
|
ifrs-full:AdjustedWeightedAverageShares |
| 78 |
1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity |
| 79 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 80 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 81 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 82 |
Share Capital $ |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 83 |
Warrants $ |
Member |
|
|
oncyf:WarrantsMember |
| 84 |
Contributed Surplus $ |
Member |
|
|
ifrs-full:SharePremiumMember |
| 85 |
Accumulated Other Comprehensive Income $ |
Member |
|
|
ifrs-full:AccumulatedOtherComprehensiveIncomeMember |
| 86 |
Accumulated Deficit $ |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 87 |
Sale Of Stock [Axis] |
Axis |
|
|
oncyf:SaleOfStockAxis |
| 88 |
Sale Of Stock [Domain] |
Member |
|
|
oncyf:SaleOfStockDomain |
| 89 |
At-the-market agreement |
Member |
|
|
oncyf:SharesUnderAtthemarketAgreementMember |
| 90 |
Public Offering |
Member |
|
|
oncyf:SharesPublicOfferingMember |
| 91 |
Share Purchase Agreement |
Member |
|
|
oncyf:SharesUnderSharePurchaseAgreementMember |
| 92 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 93 |
Equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 94 |
Net loss and other comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 95 |
Issued pursuant to incentive share award plan |
Concept (Monetary) |
For Period |
Credit |
oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity |
| 96 |
Issued pursuant to stock option plan |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions |
| 97 |
Issued |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 98 |
Issued pursuant to warrant agreement |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity |
| 99 |
Share based compensation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions |
| 100 |
Share issue costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 101 |
Equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 102 |
1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows |
| 103 |
Statement [Table] |
Table |
* |
* |
oncyf:Statement1Table |
| 104 |
Sale Of Stock [Axis] |
Axis |
|
|
oncyf:SaleOfStockAxis |
| 105 |
Sale Of Stock [Domain] |
Member |
|
|
oncyf:SaleOfStockDomain |
| 106 |
Common Stock Purchase Agreement |
Member |
|
|
oncyf:SharesUnderCommonStockPurchaseAgreementMember |
| 107 |
At-the-market agreement |
Member |
|
|
oncyf:SharesUnderAtthemarketAgreementMember |
| 108 |
Public Offering |
Member |
|
|
oncyf:SharesPublicOfferingMember |
| 109 |
Warrants |
Member |
|
|
oncyf:SharesUnderWarrantAgreementMember |
| 110 |
Statement1 [Line Items] |
LineItems |
|
|
oncyf:Statement1LineItems |
| 111 |
Operating Activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract |
| 112 |
Net loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 113 |
Depreciation - property and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense |
| 114 |
Share based compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForSharebasedPayments |
| 115 |
Unrealized foreign exchange gain |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains |
| 116 |
Onerous lease contract |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForProvisions |
| 117 |
Amortization - lease incentive liability |
Concept (Monetary) |
For Period |
Debit |
oncyf:AdjustmentsforLeaseAmortization |
| 118 |
Net change in non-cash working capital |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInWorkingCapital |
| 119 |
Cash used in operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperations |
| 120 |
Investing Activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract |
| 121 |
Acquisition of property and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 122 |
Redemption (purchase) of short-term investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments |
| 123 |
Cash (used in) provided by investing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 124 |
Financing Activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract |
| 125 |
Proceeds from share issuance |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 126 |
Proceeds from exercise of stock options |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromExerciseOfOptions |
| 127 |
Cash provided by financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 128 |
Increase (decrease) in cash |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents |
| 129 |
Cash and cash equivalents, beginning of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 130 |
Impact of foreign exchange on cash and cash equivalents |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| 131 |
Cash and cash equivalents, end of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 132 |
2101100 - Disclosure - Incorporation and Nature of Operations |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations |
| 133 |
Implied Table |
Table |
* |
* |
implied:Table |
| 134 |
Disclosure Of Notes And Other Explanatory Information [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfNotesAndOtherExplanatoryInformationAbstract |
| 135 |
Incorporation and Nature of Operations |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory |
| 136 |
2104100 - Disclosure - Basis of Financial Statement Presentation |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation |
| 137 |
Implied Table |
Table |
* |
* |
implied:Table |
| 138 |
Corporate Information And Statement Of IFRS Compliance [Abstract] |
Abstract |
|
|
oncyf:CorporateInformationAndStatementOfIFRSComplianceAbstract |
| 139 |
Basis of Financial Statement Presentation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory |
| 140 |
2107100 - Disclosure - Summary of Significant Accounting Policies |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies |
| 141 |
Implied Table |
Table |
* |
* |
implied:Table |
| 142 |
Summary Of Significant Accounting Policies [Abstract] |
Abstract |
|
|
oncyf:SummaryOfSignificantAccountingPoliciesAbstract |
| 143 |
Summary of Significant Accounting Policies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 144 |
2110100 - Disclosure - Significant Judgments, Estimates and Assumptions |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions |
| 145 |
Implied Table |
Table |
* |
* |
implied:Table |
| 146 |
Significant Judgments, Estimates And Assumptions [Abstract] |
Abstract |
|
|
oncyf:SignificantJudgmentsEstimatesAndAssumptionsAbstract |
| 147 |
Significant Judgments, Estimates and Assumptions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory |
| 148 |
2113100 - Disclosure - Cash Equivalents |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CashEquivalents |
| 149 |
Implied Table |
Table |
* |
* |
implied:Table |
| 150 |
Cash Equivalents And Short Term Investments [Abstract] |
Abstract |
|
|
oncyf:CashEquivalentsAndShortTermInvestmentsAbstract |
| 151 |
Cash Equivalents |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock |
| 152 |
2116100 - Disclosure - Property and Equipment |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/PropertyAndEquipment |
| 153 |
Implied Table |
Table |
* |
* |
implied:Table |
| 154 |
Disclosure of detailed information about property, plant and equipment [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 155 |
Property and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory |
| 156 |
2119100 - Disclosure - Share Capital |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapital |
| 157 |
Implied Table |
Table |
* |
* |
implied:Table |
| 158 |
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract] |
Abstract |
|
|
oncyf:DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract |
| 159 |
Share Capital |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory |
| 160 |
2122100 - Disclosure - Share Based Payments |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPayments |
| 161 |
Implied Table |
Table |
* |
* |
implied:Table |
| 162 |
Disclosure Of Share-based Payment Arrangements [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfSharebasedPaymentArrangementsAbstract |
| 163 |
Share Based Payments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory |
| 164 |
2125100 - Disclosure - Loss Per Common Share |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/LossPerCommonShare |
| 165 |
Implied Table |
Table |
* |
* |
implied:Table |
| 166 |
Earnings per share [abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 167 |
Loss Per Common Share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEarningsPerShareExplanatory |
| 168 |
2128100 - Disclosure - Contract Liability and Receivable |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable |
| 169 |
Implied Table |
Table |
* |
* |
implied:Table |
| 170 |
Disclosure of revenue from contracts with customers [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrevenuefromcontractswithcustomersAbstract |
| 171 |
Contract Liability and Receivable |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory |
| 172 |
2131100 - Disclosure - Commitments |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/Commitments |
| 173 |
Implied Table |
Table |
* |
* |
implied:Table |
| 174 |
Commitments [Abstract] |
Abstract |
|
|
oncyf:CommitmentsAbstract |
| 175 |
Commitments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCommitmentsExplanatory |
| 176 |
2134100 - Disclosure - Contingencies |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/Contingencies |
| 177 |
Implied Table |
Table |
* |
* |
implied:Table |
| 178 |
Contingencies [Abstract] |
Abstract |
|
|
oncyf:ContingenciesAbstract |
| 179 |
Contingencies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfContingentLiabilitiesExplanatory |
| 180 |
2137100 - Disclosure - Income Taxes |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxes |
| 181 |
Implied Table |
Table |
* |
* |
implied:Table |
| 182 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
oncyf:DisclosureofincometaxAbstract |
| 183 |
Income Taxes |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIncomeTaxExplanatory |
| 184 |
2140100 - Disclosure - Capital Disclosures |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CapitalDisclosures |
| 185 |
Implied Table |
Table |
* |
* |
implied:Table |
| 186 |
Statement of changes in equity [abstract] |
Abstract |
|
|
ifrs-full:StatementOfChangesInEquityAbstract |
| 187 |
Capital Disclosures |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory |
| 188 |
2143100 - Disclosure - Financial Instruments |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/FinancialInstruments |
| 189 |
Implied Table |
Table |
* |
* |
implied:Table |
| 190 |
Disclosure of detailed information about financial instruments [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 191 |
Financial Instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsExplanatory |
| 192 |
2146100 - Disclosure - Additional Cash Flow Disclosures |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures |
| 193 |
Implied Table |
Table |
* |
* |
implied:Table |
| 194 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 195 |
Additional Cash Flow Disclosures |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCashFlowStatementExplanatory |
| 196 |
2149100 - Disclosure - Indemnification of Officers and Directors |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors |
| 197 |
Implied Table |
Table |
* |
* |
implied:Table |
| 198 |
Disclosure Of Indemnification Of Officers and Directors [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsAbstract |
| 199 |
Indemnification of Officers and Directors |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock |
| 200 |
2152100 - Disclosure - Economic Dependence |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/EconomicDependence |
| 201 |
Implied Table |
Table |
* |
* |
implied:Table |
| 202 |
Disclosure Of Economic Dependence [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfEconomicDependenceAbstract |
| 203 |
Economic Dependence |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:DisclosureOfEconomicDependenceTextBlock |
| 204 |
2155100 - Disclosure - Other Expenses and Adjustments |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments |
| 205 |
Implied Table |
Table |
* |
* |
implied:Table |
| 206 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 207 |
Other Expenses and Adjustments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory |
| 208 |
2156100 - Disclosure - Related Party Transactions |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions |
| 209 |
Implied Table |
Table |
* |
* |
implied:Table |
| 210 |
Disclosure of related party [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrelatedpartyAbstract |
| 211 |
Related Party Transactions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRelatedPartyExplanatory |
| 212 |
2207201 - Disclosure - Summary of Significant Accounting Policies (Policies) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies |
| 213 |
Implied Table |
Table |
* |
* |
implied:Table |
| 214 |
Summary Of Significant Accounting Policie [Abstract] |
Abstract |
|
|
oncyf:SummaryOfSignificantAccountingPolicieAbstract |
| 215 |
Deferred income taxes |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory |
| 216 |
Financial assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory |
| 217 |
Financial liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory |
| 218 |
Impairment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory |
| 219 |
Fair value measurement |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory |
| 220 |
Foreign currency translation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory |
| 221 |
Investment tax credits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory |
| 222 |
Loss per common share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory |
| 223 |
Property and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory |
| 224 |
Research and development costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory |
| 225 |
Revenue recognition |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue |
| 226 |
Share based payments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory |
| 227 |
Adoption of new accounting standards |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations |
| 228 |
Accounting standards and interpretations issued but not yet effective |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations |
| 229 |
2307302 - Disclosure - Summary of Significant Accounting Policies (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables |
| 230 |
Implied Table |
Table |
* |
* |
implied:Table |
| 231 |
Summary Of Significant Accounting Policies [Abstract] |
Abstract |
|
|
oncyf:SummaryOfSignificantAccountingPoliciesAbstract |
| 232 |
Schedule of depreciation rates |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 233 |
2316301 - Disclosure - Property and Equipment (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables |
| 234 |
Implied Table |
Table |
* |
* |
implied:Table |
| 235 |
Disclosure of detailed information about property, plant and equipment [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 236 |
Schedule of property and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 237 |
2319301 - Disclosure - Share Capital (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapitalTables |
| 238 |
Implied Table |
Table |
* |
* |
implied:Table |
| 239 |
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract] |
Abstract |
|
|
oncyf:DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract |
| 240 |
Schedule of share capital |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory |
| 241 |
Summary of Outstanding Warrants |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory |
| 242 |
2322301 - Disclosure - Share Based Payments (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables |
| 243 |
Implied Table |
Table |
* |
* |
implied:Table |
| 244 |
Disclosure of share-based payment arrangement [Abstract] |
Abstract |
|
|
oncyf:DisclosureofsharebasedpaymentarrangementAbstract |
| 245 |
Schedule of stock options and weighted average exercise prices of share options |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory |
| 246 |
Schedule of stock options outstanding and exercisable by range of exercise price |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory |
| 247 |
Schedule of weighted average remaining contractual life and outstanding stock options by exercise price |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory |
| 248 |
Disclosure weighted average assumptions and fair value of options |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory |
| 249 |
Schedule of number of other equity instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory |
| 250 |
2328301 - Disclosure - Contract Liability and Receivable (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables |
| 251 |
Implied Table |
Table |
* |
* |
implied:Table |
| 252 |
Disclosure of revenue from contracts with customers [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrevenuefromcontractswithcustomersAbstract |
| 253 |
Contract liability balances |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory |
| 254 |
2331301 - Disclosure - Commitments (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CommitmentsTables |
| 255 |
Implied Table |
Table |
* |
* |
implied:Table |
| 256 |
Commitments [Abstract] |
Abstract |
|
|
oncyf:CommitmentsAbstract |
| 257 |
Disclosure of rental payments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory |
| 258 |
2337301 - Disclosure - Income Taxes (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxesTables |
| 259 |
Implied Table |
Table |
* |
* |
implied:Table |
| 260 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
oncyf:DisclosureofincometaxAbstract |
| 261 |
Provision for income taxes |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock |
| 262 |
Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory |
| 263 |
2340301 - Disclosure - Capital Disclosures (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables |
| 264 |
Implied Table |
Table |
* |
* |
implied:Table |
| 265 |
Statement of changes in equity [abstract] |
Abstract |
|
|
ifrs-full:StatementOfChangesInEquityAbstract |
| 266 |
Schedule of capital components |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:DisclosureOfCapitalComponentsTableTextBlock |
| 267 |
2343301 - Disclosure - Financial Instruments (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables |
| 268 |
Implied Table |
Table |
* |
* |
implied:Table |
| 269 |
Disclosure of detailed information about financial instruments [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 270 |
Schedule of balances in foreign currencies |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock |
| 271 |
2346301 - Disclosure - Additional Cash Flow Disclosures (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables |
| 272 |
Implied Table |
Table |
* |
* |
implied:Table |
| 273 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 274 |
Net change in non-cash working capital |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:CashFlowOperatingCapital1TableTextBlock |
| 275 |
Other cash flow disclosures |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock |
| 276 |
2355301 - Disclosure - Other Expenses and Adjustments (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables |
| 277 |
Implied Table |
Table |
* |
* |
implied:Table |
| 278 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 279 |
Other expenses and adjustments |
Concept (Text Block (HTML)) |
For Period |
|
oncyf:OtherExpensesAndAdjustmentsTableTextBlock |
| 280 |
2356301 - Disclosure - Related Party Transactions (Tables) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables |
| 281 |
Implied Table |
Table |
* |
* |
implied:Table |
| 282 |
Disclosure of related party [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrelatedpartyAbstract |
| 283 |
Schedule of related party transactions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory |
| 284 |
2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails |
| 285 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 286 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 287 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 288 |
Office equipment and furniture |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 289 |
Medical equipment |
Member |
|
|
oncyf:MedicalEquipmentMember |
| 290 |
Computer equipment |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 291 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 292 |
Annual depreciation rate |
Concept (Percent) |
For Period |
|
oncyf:PropertyPlantandEquipmentAnnualDepreciationRate |
| 293 |
2407404 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails |
| 294 |
Implied Table |
Table |
* |
* |
implied:Table |
| 295 |
Summary Of Significant Accounting Policie [Abstract] |
Abstract |
|
|
oncyf:SummaryOfSignificantAccountingPolicieAbstract |
| 296 |
Number of plans |
Concept (Integer) |
As Of |
|
oncyf:NumberOfStockOptionPlans |
| 297 |
Maximum option expiration term |
Concept (xbrli:durationItemType) |
For Period |
|
oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement |
| 298 |
2413401 - Disclosure - Cash Equivalents - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails |
| 299 |
Implied Table |
Table |
* |
* |
implied:Table |
| 300 |
Cash Equivalents And Short Term Investments [Abstract] |
Abstract |
|
|
oncyf:CashEquivalentsAndShortTermInvestmentsAbstract |
| 301 |
Cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashEquivalents |
| 302 |
Current annual interest rate |
Concept (Percent) |
For Period |
|
oncyf:CashEquivalentsInterestRate |
| 303 |
2416402 - Disclosure - Property and Equipment (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails |
| 304 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 305 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 306 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 307 |
Medical equipment |
Member |
|
|
oncyf:MedicalEquipmentMember |
| 308 |
Computer equipment |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 309 |
Office Furniture |
Member |
|
|
ifrs-full:FixturesAndFittingsMember |
| 310 |
Office Equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 311 |
Leasehold Improvements |
Member |
|
|
ifrs-full:LeaseholdImprovementsMember |
| 312 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 313 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 314 |
Cost |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 315 |
Amortization |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 316 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 317 |
Reconciliation of changes in property, plant and equipment [abstract] |
Abstract |
|
|
ifrs-full:ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract |
| 318 |
Property and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 319 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment |
| 320 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 321 |
Property and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 322 |
2419402 - Disclosure - Share Capital - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails |
| 323 |
Implied Table |
Table |
* |
* |
implied:Table |
| 324 |
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract] |
Abstract |
|
|
oncyf:DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract |
| 325 |
Stock conversion ratio |
Concept (Pure) |
For Period |
|
oncyf:StockholdersEquityNoteStockSplitConversionRatio |
| 326 |
Warrants exercisable into common shares |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 327 |
Number of common shares issuable per warrant |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 |
| 328 |
2419403 - Disclosure - Share Capital - Schedule of Share Capital (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails |
| 329 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 330 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 331 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 332 |
Pre-Consolidation |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 333 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 334 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 335 |
Shares |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 336 |
Warrants |
Member |
|
|
oncyf:WarrantsMember |
| 337 |
Sale Of Stock [Axis] |
Axis |
|
|
oncyf:SaleOfStockAxis |
| 338 |
Sale Of Stock [Domain] |
Member |
|
|
oncyf:SaleOfStockDomain |
| 339 |
Incentive award plan |
Member |
|
|
oncyf:SharesUnderIncentiveAwardPlanMember |
| 340 |
Common Stock Purchase Agreement |
Member |
|
|
oncyf:SharesUnderCommonStockPurchaseAgreementMember |
| 341 |
At-the-market agreement |
Member |
|
|
oncyf:SharesUnderAtthemarketAgreementMember |
| 342 |
Stock option plan |
Member |
|
|
oncyf:SharesUnderStockOptionPlanMember |
| 343 |
Public Offering |
Member |
|
|
oncyf:SharesPublicOfferingMember |
| 344 |
Warrants |
Member |
|
|
oncyf:SharesUnderWarrantAgreementMember |
| 345 |
Share Purchase Agreement |
Member |
|
|
oncyf:SharesUnderSharePurchaseAgreementMember |
| 346 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 347 |
Number of common shares issuable per warrant |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 |
| 348 |
Equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 349 |
Share capital issued, beginning (shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 350 |
Issued shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 351 |
Issued (shares) |
Concept (Shares) |
For Period |
|
oncyf:IssueOfEquityShares |
| 352 |
Gross proceeds from common shares |
Concept (Monetary) |
For Period |
Debit |
oncyf:GrossProceedsFromIssueOfOrdinaryShares |
| 353 |
Share issue costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 354 |
Equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 355 |
Share capital issued ending (shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 356 |
2419404 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails |
| 357 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 358 |
Sale Of Stock [Axis] |
Axis |
|
|
oncyf:SaleOfStockAxis |
| 359 |
Sale Of Stock [Domain] |
Member |
|
|
oncyf:SaleOfStockDomain |
| 360 |
Canadian ATM |
Member |
|
|
oncyf:SharesUnderAtthemarketAgreementCanadianMember |
| 361 |
United States ATM |
Member |
|
|
oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember |
| 362 |
Public Offering |
Member |
|
|
oncyf:SharesPublicOfferingMember |
| 363 |
Agreement |
Member |
|
|
oncyf:SharesUnderCommonStockPurchaseAgreementMember |
| 364 |
Initial commitment fee |
Member |
|
|
oncyf:InitialCommitmentFeeMember |
| 365 |
Additional commitment fee |
Member |
|
|
oncyf:AdditionalCommitmentFeeMember |
| 366 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 367 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 368 |
Pre-Consolidation |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 369 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 370 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 371 |
Warrants |
Member |
|
|
oncyf:WarrantsMember |
| 372 |
Shares |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 373 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 374 |
Equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 375 |
Issued (shares) |
Concept (Shares) |
For Period |
|
oncyf:IssueOfEquityShares |
| 376 |
Gross proceeds from common shares |
Concept (Monetary) |
For Period |
Debit |
oncyf:GrossProceedsFromIssueOfOrdinaryShares |
| 377 |
Share issue related cost |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 378 |
Purchase price (cad per share) |
Concept (Share) |
As Of |
|
oncyf:SharesIssuedPricePerShare1 |
| 379 |
Common shares per unit |
Concept (Shares) |
As Of |
|
oncyf:CommonSharesPerUnit |
| 380 |
Common share purchase warrant per unit |
Concept (Shares) |
As Of |
|
oncyf:CommonSharePurchaseWarrantPerUnit |
| 381 |
Purchase price (cad per share) |
Concept (Share) |
As Of |
|
oncyf:SharesIssuedWarrantPricePerShare |
| 382 |
Number of common shares issuable per warrant |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 |
| 383 |
Exercise price (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:ExercisePriceOfOutstandingShareOptions |
| 384 |
Warrants exercisable into common shares |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 385 |
Acceleration threshold weighted average price (cad per share) |
Concept (Share) |
As Of |
|
oncyf:WarrantPricePerShareAccelerationThreshold |
| 386 |
Acceleration threshold weighted average price, trading days |
Concept (Decimal) |
As Of |
|
oncyf:WarrantPricePerShareAccelerationThresholdTradingDays |
| 387 |
Agreement |
Concept (Monetary) |
As Of |
Credit |
oncyf:SharePurchaseAgreementAmount |
| 388 |
Agreement term |
Concept (xbrli:durationItemType) |
For Period |
|
oncyf:SharePurchaseAgreementTerm |
| 389 |
Proceeds from shares issued under Share Purchase Agreement |
Concept (Monetary) |
For Period |
Debit |
oncyf:InitialCommitmentFeeSharesIssuedFairValue |
| 390 |
Future issuance pursuant to Share Purchase Agreement (shares) |
Concept (Shares) |
For Period |
|
oncyf:IssueOfEquitySharePurchaseAgreementFutureIssuesShares |
| 391 |
2419405 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails |
| 392 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 393 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 394 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 395 |
Warrants |
Member |
|
|
oncyf:WarrantsMember |
| 396 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 397 |
Exercise Price |
Concept (Monetary) |
As Of |
Debit |
oncyf:ExercisePriceofOutstandingWarrants |
| 398 |
Share capital issued, beginning (shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 399 |
Issued (shares) |
Concept (Shares) |
For Period |
|
oncyf:IssueOfEquityShares |
| 400 |
Share capital issued ending (shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 401 |
Weighted average remaining contractual life of outstanding share options |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 402 |
Warrants exercisable into common shares |
Concept (Shares) |
As Of |
|
oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 403 |
2422402 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails |
| 404 |
Implied Table |
Table |
* |
* |
implied:Table |
| 405 |
Disclosure Of Share-based Payment Arrangements [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfSharebasedPaymentArrangementsAbstract |
| 406 |
Outstanding, beginning of the year (shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 407 |
Granted during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 408 |
Forfeited during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 409 |
Expired during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 410 |
Exercised during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 411 |
Outstanding, end of the year (shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 412 |
Options exercisable, end of the year (shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 413 |
Outstanding, beginning of the year (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 414 |
Granted during the year (cad per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 415 |
Forfeited during the year (cad per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 416 |
Expired during the year (cad per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 417 |
Exercised during the year (cad per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 418 |
Outstanding, end of the year (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 419 |
Options exercisable, end of the year (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 420 |
2422403 - Disclosure - Share Based Payments - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails |
| 421 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 422 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 423 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 424 |
Minimum |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 425 |
Maximum |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 426 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 427 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 428 |
Restricted share units |
Member |
|
|
oncyf:RestrictedShareUnitsMember |
| 429 |
Performance share units |
Member |
|
|
oncyf:PerformanceShareUnitsMember |
| 430 |
Reserve of share-based payments |
Member |
|
|
ifrs-full:ReserveOfSharebasedPaymentsMember |
| 431 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 432 |
Stock conversion ratio |
Concept (Pure) |
For Period |
|
oncyf:StockholdersEquityNoteStockSplitConversionRatio |
| 433 |
Vesting period |
Concept (Decimal) |
For Period |
|
oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 |
| 434 |
Common shares reserved for issuance |
Concept (Shares) |
As Of |
|
ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares |
| 435 |
2422404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails |
| 436 |
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable |
| 437 |
Ranges of exercise prices for outstanding share options [axis] |
Axis |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis |
| 438 |
Ranges of exercise prices for outstanding share options [member] |
Member |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember |
| 439 |
$2.47 - $3.99 |
Member |
|
|
oncyf:ExercisePriceRangeOneMember |
| 440 |
$4.84 - $7.81 |
Member |
|
|
oncyf:ExercisePriceRangeTwoMember |
| 441 |
$13.77 - $19.00 |
Member |
|
|
oncyf:ExercisePriceRangeThreeMember |
| 442 |
$20.23 - $36.96 |
Member |
|
|
oncyf:ExercisePriceRangeFourMember |
| 443 |
$38.09 - $63.84 |
Member |
|
|
oncyf:ExercisePriceRangeFiveMember |
| 444 |
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems |
| 445 |
Number Outstanding (options) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 446 |
Weighted Average Remaining Contractual Life (years) |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 447 |
Weighted Average Exercise Price (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 448 |
Number Exercisable (options) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 449 |
Weighted Average Exercise Price (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 450 |
2422404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails |
| 451 |
Disclosure of range of exercise prices of outstanding share options [table] |
Table |
* |
* |
ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable |
| 452 |
Ranges of exercise prices for outstanding share options [axis] |
Axis |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis |
| 453 |
Ranges of exercise prices for outstanding share options [member] |
Member |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember |
| 454 |
$2.47 - $3.99 |
Member |
|
|
oncyf:ExercisePriceRangeOneMember |
| 455 |
$4.84 - $7.81 |
Member |
|
|
oncyf:ExercisePriceRangeTwoMember |
| 456 |
$13.77 - $19.00 |
Member |
|
|
oncyf:ExercisePriceRangeThreeMember |
| 457 |
$20.23 - $36.96 |
Member |
|
|
oncyf:ExercisePriceRangeFourMember |
| 458 |
$38.09 - $63.84 |
Member |
|
|
oncyf:ExercisePriceRangeFiveMember |
| 459 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 460 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 461 |
Minimum |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 462 |
Maximum |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 463 |
Disclosure of range of exercise prices of outstanding share options [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems |
| 464 |
Exercise price (cad per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:ExercisePriceOfOutstandingShareOptions |
| 465 |
2422405 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails |
| 466 |
Implied Table |
Table |
* |
* |
implied:Table |
| 467 |
Disclosure Of Share-based Payment Arrangements [Abstract] |
Abstract |
|
|
oncyf:DisclosureOfSharebasedPaymentArrangementsAbstract |
| 468 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 469 |
Expected hold period to exercise |
Concept (Decimal) |
For Period |
|
ifrs-full:DescriptionOfOptionLifeShareOptionsGranted |
| 470 |
Volatility in the price of the Company's shares |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 471 |
Rate of forfeiture |
Concept (Percent) |
For Period |
|
oncyf:ExpectedForfeitureShareOptionsGranted |
| 472 |
Dividend yield |
Concept (Percent) |
For Period |
|
ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted |
| 473 |
Weighted average fair value of options (cad per share) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted |
| 474 |
2422406 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails |
| 475 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 476 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 477 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 478 |
Restricted share units |
Member |
|
|
oncyf:RestrictedShareUnitsMember |
| 479 |
Performance share units |
Member |
|
|
oncyf:PerformanceShareUnitsMember |
| 480 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 481 |
Outstanding, beginning of the year (shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 482 |
Granted during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted |
| 483 |
Forfeited during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement |
| 484 |
Vested during the year (shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement |
| 485 |
Outstanding, end of the year (shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 486 |
Weighted average fair value at measurement date, other equity instruments granted |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted |
| 487 |
2425401 - Disclosure - Loss Per Common Share (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails |
| 488 |
Implied Table |
Table |
* |
* |
implied:Table |
| 489 |
Earnings per share [abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 490 |
Weighted average number of common shares outstanding |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 491 |
2428402 - Disclosure - Contract Liability and Receivable - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails |
| 492 |
Class of Warrant or Right1 [Table] |
Table |
* |
* |
oncyf:ClassofWarrantorRight1Table |
| 493 |
Milestone [Axis] |
Axis |
|
|
oncyf:MilestoneAxis |
| 494 |
Milestone [Domain] |
Member |
|
|
oncyf:MilestoneDomain |
| 495 |
Milestone 1 |
Member |
|
|
oncyf:MilestoneOneMember |
| 496 |
Milestone 2 |
Member |
|
|
oncyf:MilestoneTwoMember |
| 497 |
Class of Warrant or Right1 [Line Items] |
LineItems |
|
|
oncyf:ClassofWarrantorRight1LineItems |
| 498 |
Warrant purchase agreement |
Concept (Monetary) |
For Period |
Debit |
oncyf:WarrantPurchaseAgreement |
| 499 |
Common share premium |
Concept (Percent) |
For Period |
|
oncyf:SharePricePremiumPercent |
| 500 |
Weighted average closing price term |
Concept (Decimal) |
For Period |
|
oncyf:WeightedAverageClosingPriceDuration |
| 501 |
Patients |
Concept (Integer) |
For Period |
|
oncyf:NumberofPatients |
| 502 |
Right to call warrant from time of agreement, term |
Concept (Decimal) |
For Period |
|
oncyf:RighttoCallWarrantMilestoneOneTerm |
| 503 |
2428403 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails |
| 504 |
Implied Table |
Table |
* |
* |
implied:Table |
| 505 |
Disclosure of revenue from contracts with customers [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrevenuefromcontractswithcustomersAbstract |
| 506 |
Balance, beginning of the year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContractLiabilities |
| 507 |
Regional licensing agreement |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromContractsWithCustomers |
| 508 |
Revenue recognized in the year |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities |
| 509 |
Balance, end of the year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContractLiabilities |
| 510 |
Contract liability - current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentContractLiabilities |
| 511 |
Contract liability - non-current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentContractLiabilities |
| 512 |
Contract liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContractLiabilities |
| 513 |
2431402 - Disclosure - Commitments (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CommitmentsDetails |
| 514 |
Disclosure of maturity analysis of operating lease payments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable |
| 515 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 516 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 517 |
2019 |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 518 |
2020 |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 519 |
2021 |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 520 |
Disclosure of maturity analysis of operating lease payments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems |
| 521 |
Rental payments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease |
| 522 |
2434401 - Disclosure - Contingencies (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/ContingenciesDetails |
| 523 |
Disclosure of contingent liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfContingentLiabilitiesTable |
| 524 |
Counterparties [axis] |
Axis |
|
|
ifrs-full:CounterpartiesAxis |
| 525 |
Counterparties [member] |
Member |
|
|
ifrs-full:CounterpartiesMember |
| 526 |
SYNSORB |
Member |
|
|
oncyf:SYNSORBMember |
| 527 |
Disclosure of contingent liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfContingentLiabilitiesLineItems |
| 528 |
Milestone payment in connection with Share Purchase Agreement |
Concept (Monetary) |
For Period |
|
ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions |
| 529 |
Payment due period |
Concept (xbrli:durationItemType) |
For Period |
|
oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue |
| 530 |
Royalty payment due to founding shareholders, percent |
Concept (Percent) |
For Period |
|
oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage |
| 531 |
Royalty payment on net sales due to founding shareholders, percent |
Concept (Percent) |
For Period |
|
oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage |
| 532 |
2437402 - Disclosure - Income Taxes - Provision for Income Taxes (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails |
| 533 |
Implied Table |
Table |
* |
* |
implied:Table |
| 534 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
oncyf:DisclosureofincometaxAbstract |
| 535 |
Loss before income taxes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AccountingProfit |
| 536 |
Statutory Canadian corporate tax rate |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 537 |
Anticipated tax recovery |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxExpenseIncomeAtApplicableTaxRate |
| 538 |
Foreign jurisdiction tax rate difference |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfForeignTaxRates |
| 539 |
Employee stock based compensation |
Concept (Monetary) |
For Period |
Credit |
oncyf:TaxEffectOfStockBasedCompensation |
| 540 |
Adjustment to opening tax pools |
Concept (Monetary) |
For Period |
Debit |
oncyf:TaxEffectOfTaxPools |
| 541 |
Other permanent differences |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss |
| 542 |
Change in deferred tax benefits deemed not probable to be recovered |
Concept (Monetary) |
For Period |
Credit |
oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 |
| 543 |
Current income taxes |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncome |
| 544 |
Adjustment in respect to prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 545 |
Net current tax expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods |
| 546 |
2437403 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails |
| 547 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 548 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 549 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 550 |
2026 |
Member |
|
|
oncyf:TwentyTwentySixMember |
| 551 |
2027 |
Member |
|
|
oncyf:TwentyTwentySevenMember |
| 552 |
2029 |
Member |
|
|
oncyf:TwentyTwentyNineMember |
| 553 |
2030 |
Member |
|
|
oncyf:TwentyThirtyMember |
| 554 |
2031 |
Member |
|
|
oncyf:TwentyThirtyOneMember |
| 555 |
2032 |
Member |
|
|
oncyf:TwentyThirtyTwoMember |
| 556 |
2033 |
Member |
|
|
oncyf:TwentyThirtyThreeMember |
| 557 |
2034 |
Member |
|
|
oncyf:TwentyThirtyFourMember |
| 558 |
2035 |
Member |
|
|
oncyf:TwentyThirtyFiveMember |
| 559 |
2036 |
Member |
|
|
oncyf:TwentyThirtySixMember |
| 560 |
2037 |
Member |
|
|
oncyf:TwentyThirtySevenMember |
| 561 |
2038 |
Member |
|
|
oncyf:TwentyThirtyEightMember |
| 562 |
Temporary difference, unused tax losses and unused tax credits [axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 563 |
Temporary difference, unused tax losses and unused tax credits [member] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 564 |
Non-capital losses |
Member |
|
|
ifrs-full:UnusedTaxLossesMember |
| 565 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 566 |
Unused tax losses |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised |
| 567 |
2437404 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails |
| 568 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 569 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 570 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 571 |
2020 |
Member |
|
|
oncyf:TwentyTwentyMember |
| 572 |
2021 |
Member |
|
|
oncyf:TwentyTwentyOneMember |
| 573 |
2022 |
Member |
|
|
oncyf:TwentyTwentyTwoMember |
| 574 |
2023 |
Member |
|
|
oncyf:TwentyTwentyThreeMember |
| 575 |
2024 |
Member |
|
|
oncyf:TwentyTwentyFourMember |
| 576 |
2025 |
Member |
|
|
oncyf:TwentyTwentyFiveMember |
| 577 |
2026 |
Member |
|
|
oncyf:TwentyTwentySixMember |
| 578 |
2027 |
Member |
|
|
oncyf:TwentyTwentySevenMember |
| 579 |
2028 |
Member |
|
|
oncyf:TwentyTwentyEightMember |
| 580 |
2029 |
Member |
|
|
oncyf:TwentyTwentyNineMember |
| 581 |
2030 |
Member |
|
|
oncyf:TwentyThirtyMember |
| 582 |
2031 |
Member |
|
|
oncyf:TwentyThirtyOneMember |
| 583 |
2032 |
Member |
|
|
oncyf:TwentyThirtyTwoMember |
| 584 |
2033 |
Member |
|
|
oncyf:TwentyThirtyThreeMember |
| 585 |
2034 |
Member |
|
|
oncyf:TwentyThirtyFourMember |
| 586 |
2035 |
Member |
|
|
oncyf:TwentyThirtyFiveMember |
| 587 |
2036 |
Member |
|
|
oncyf:TwentyThirtySixMember |
| 588 |
2037 |
Member |
|
|
oncyf:TwentyThirtySevenMember |
| 589 |
Temporary difference, unused tax losses and unused tax credits [axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 590 |
Temporary difference, unused tax losses and unused tax credits [member] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 591 |
Non-refundable federal investment tax credits |
Member |
|
|
ifrs-full:UnusedTaxCreditsMember |
| 592 |
Unclaimed scientific research and experimental development expenditures |
Member |
|
|
oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember |
| 593 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 594 |
Unused tax credits |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised |
| 595 |
2437405 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails |
| 596 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 597 |
Temporary difference, unused tax losses and unused tax credits [axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 598 |
Temporary difference, unused tax losses and unused tax credits [member] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 599 |
Net operating losses carried forward |
Member |
|
|
oncyf:UnusedNetOperatingLossCarryForwardsMember |
| 600 |
Scientific research and experimental development |
Member |
|
|
oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember |
| 601 |
Investment tax credits |
Member |
|
|
oncyf:InvestmentTaxCreditsMember |
| 602 |
Undepreciated capital costs in excess of book value of property and equipment and intellectual property |
Member |
|
|
oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember |
| 603 |
Share issue costs |
Member |
|
|
oncyf:ShareIssueCostsMember |
| 604 |
Net capital losses carried forward |
Member |
|
|
oncyf:UnusedCapitalLossCarryForwardNetMember |
| 605 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 606 |
Unrecognized deferred tax asset |
Concept (Monetary) |
As Of |
|
ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised |
| 607 |
2440402 - Disclosure - Capital Disclosures (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails |
| 608 |
Implied Table |
Table |
* |
* |
implied:Table |
| 609 |
Statement of changes in equity [abstract] |
Abstract |
|
|
ifrs-full:StatementOfChangesInEquityAbstract |
| 610 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 611 |
Short-term investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentInvestments |
| 612 |
Shareholders’ equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 613 |
Base Shelf securities authorized |
Concept (Monetary) |
As Of |
Credit |
oncyf:EquityAuthorized |
| 614 |
2443402 - Disclosure - Financial Instruments - Narrative (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails |
| 615 |
Disclosure of nature and extent of risks arising from financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable |
| 616 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 617 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 618 |
Currency risk |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 619 |
Currency1 [Axis] |
Axis |
|
|
oncyf:Currency1Axis |
| 620 |
All Currencies [Domain] |
Member |
|
|
currency:AllCurrenciesDomain |
| 621 |
US dollars $ |
Member |
|
|
currency:USD |
| 622 |
British pounds £ |
Member |
|
|
currency:GBP |
| 623 |
Euro € |
Member |
|
|
currency:EUR |
| 624 |
Disclosure of nature and extent of risks arising from financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems |
| 625 |
Impact of increase in value of currency, amount |
Concept (Monetary) |
For Period |
|
oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount |
| 626 |
(Increase) decrease in net loss due to change in currency value |
Concept (Monetary) |
For Period |
Credit |
oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings |
| 627 |
2443403 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails |
| 628 |
Currency1 [Table] |
Table |
* |
* |
oncyf:Currency1Table |
| 629 |
Currency1 [Axis] |
Axis |
|
|
oncyf:Currency1Axis |
| 630 |
All Currencies [Domain] |
Member |
|
|
currency:AllCurrenciesDomain |
| 631 |
US dollars $ |
Member |
|
|
currency:USD |
| 632 |
British pounds £ |
Member |
|
|
currency:GBP |
| 633 |
Euro € |
Member |
|
|
currency:EUR |
| 634 |
Currency1 [Line Items] |
LineItems |
|
|
oncyf:Currency1LineItems |
| 635 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 636 |
Accounts payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayablesToTradeSuppliers |
| 637 |
Balances in foreign currencies |
Concept (Monetary) |
As Of |
Debit |
oncyf:BalanceHeldInForeignCurrencyNet |
| 638 |
2446402 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails |
| 639 |
Implied Table |
Table |
* |
* |
implied:Table |
| 640 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 641 |
Contract receivable |
Concept (Monetary) |
For Period |
Debit |
oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable |
| 642 |
Other receivables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables |
| 643 |
Prepaid expenses |
Concept (Monetary) |
For Period |
Debit |
oncyf:IncreaseDecreaseinPrepaidExpense1 |
| 644 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables |
| 645 |
Contract liability |
Concept (Monetary) |
For Period |
Debit |
oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities |
| 646 |
Other liabilities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables |
| 647 |
Non-cash impact of foreign exchange |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets |
| 648 |
Change in non-cash working capital related to operating activities |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInWorkingCapital |
| 649 |
2446403 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails |
| 650 |
Implied Table |
Table |
* |
* |
implied:Table |
| 651 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 652 |
Cash interest received |
Concept (Monetary) |
For Period |
Debit |
oncyf:ProceedsfromInterestReceived |
| 653 |
Cash taxes paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncomeTaxesPaidRefund |
| 654 |
2452401 - Disclosure - Economic Dependence (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails |
| 655 |
Concentration Risk1 [Table] |
Table |
* |
* |
oncyf:ConcentrationRisk1Table |
| 656 |
Concentration Risk Type1 [Axis] |
Axis |
|
|
oncyf:ConcentrationRiskType1Axis |
| 657 |
Concentration Risk Type1 [Domain] |
Member |
|
|
oncyf:ConcentrationRiskType1Domain |
| 658 |
Toll manufacturer |
Member |
|
|
oncyf:SupplierConcentrationRisk1Member |
| 659 |
Concentration Risk Type1 [Line Items] |
LineItems |
|
|
oncyf:ConcentrationRiskType1LineItems |
| 660 |
Concentration, number |
Concept (Integer) |
For Period |
|
oncyf:ConcentrationRiskNumber |
| 661 |
2455402 - Disclosure - Other Expenses and Adjustments (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails |
| 662 |
Other Expenses And Adjustments [Table] |
Table |
* |
* |
oncyf:OtherExpensesAndAdjustmentsTable |
| 663 |
Income Statement Location [Axis] |
Axis |
|
|
oncyf:IncomeStatementLocation1Axis |
| 664 |
Income Statement Location [Domain] |
Member |
|
|
oncyf:IncomeStatementLocation1Domain |
| 665 |
Included in research and development expenses: |
Member |
|
|
oncyf:ResearchAndDevelopmentMember |
| 666 |
Included in operating expenses |
Member |
|
|
oncyf:OperatingExpensesMember |
| 667 |
Other Expenses And Adjustments [Line Items] |
LineItems |
|
|
oncyf:OtherExpensesAndAdjustmentsLineItems |
| 668 |
Realized foreign exchange (gain) loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 669 |
Unrealized non-cash foreign exchange (gain) loss |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains |
| 670 |
Non-cash share based compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 671 |
Depreciation - property and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AmortisationExpense |
| 672 |
Office minimum lease payments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense |
| 673 |
Onerous lease contract |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForProvisions |
| 674 |
Amortization - lease incentive liability |
Concept (Monetary) |
For Period |
Debit |
oncyf:AdjustmentsforLeaseAmortization |
| 675 |
2456402 - Disclosure - Related Party Transactions (Details) |
Network |
* |
* |
http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails |
| 676 |
Implied Table |
Table |
* |
* |
implied:Table |
| 677 |
Disclosure of related party [Abstract] |
Abstract |
|
|
oncyf:DisclosureofrelatedpartyAbstract |
| 678 |
Short-term employee compensation and benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits |
| 679 |
Termination benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits |
| 680 |
Share-based payments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment |
| 681 |
Compensation of key management personnel |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensation |
| 682 |
Liability to officer |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties |
| 683 |
Officer liability paid |
Concept (Monetary) |
For Period |
Debit |
oncyf:RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1 |